GlassScriptPhysician profile
Michael S Mamoun
NPI 1326332008
$4,956.14
in general payments reported to CMS, 2019-2025
41 companies · $921 in 2025
The $921 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $173 · 2021: $261 · 2022: $850 · 2023: $674 · 2024: $1,254 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,821 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,821.17 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,008.91 | 2019-2025 | Hizentra |
| Abbvie INC. | $923.89 | 2021-2025 | |
| Lundbeck LLC | $247.48 | 2019-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $225.97 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Merz Pharmaceuticals, LLC | $188.70 | 2022-2024 | Xeomin |
| Teva Pharmaceuticals USA, INC. | $184.47 | 2019-2024 | Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $182.41 | 2024-2025 | Cobenfy |
| Amgen INC. | $181.05 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $160.76 | 2024-2025 | Caplyta |
| Argenx US, INC. | $155.90 | 2024-2025 | Vyvgart Hytrulo |
| Collegium Pharmaceutical, INC. | $136.26 | 2019-2025 | Jornay Pm |
| Avanos Medical | $130.94 | 2024 | Generator |
| Ipsen Biopharmaceuticals, INC | $128.75 | 2019-2022 | |
| Allergan, INC. | $93.37 | 2019-2020 | |
| Sk Life Science, INC. | $92.17 | 2022-2023 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mamoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.